dronabinol has been researched along with hydromorphone in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (8.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 3 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Johnstone, RE; Kulp, RA; Lief, PL; Smith, TC | 1 |
| Faugno, D; Gaensslen, RE; Greene, P; Haner, B; Juhascik, MP; Ledray, L; Lindner, A; Negrusz, A | 1 |
| Hays, LR; Kelly, TH; Lile, JA; Pinsky, DJ | 1 |
| Hays, LR; Kelly, TH; Lile, JA | 1 |
| Bergeria, CL; Campbell, CM; Dunn, KE; Huhn, AS; Mun, CJ; Speed, TJ; Vandrey, R | 1 |
| Coulter, C; Garnier, M; Moore, C | 1 |
| Bergeria, CL; Campbell, CM; Dunn, KE; Hamilton, KR; Huhn, AS; Mun, CJ; Speed, TJ; Vandrey, R | 1 |
1 review(s) available for dronabinol and hydromorphone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
4 trial(s) available for dronabinol and hydromorphone
| Article | Year |
|---|---|
Combination of delta9-tetrahydrocannabinol with oxymorphone or pentobarbital: Effects on ventilatory control and cardiovascular dynamics.
Topics: Adult; Blood Pressure; Cannabis; Cardiac Output; Clinical Trials as Topic; Dose-Response Relationship, Drug; Dronabinol; Drug Synergism; Emotions; Heart Rate; Hemodynamics; Humans; Hydromorphone; Injections, Intravenous; Male; Nausea; Oxymorphone; Pentobarbital; Pulmonary Ventilation; Respiration; Vascular Resistance | 1975 |
The reinforcing, self-reported performance and physiological effects of Delta9-tetrahydrocannabinol, triazolam, hydromorphone, and methylphenidate in cannabis users.
Topics: Adult; Analgesics, Opioid; Blood Pressure; Body Temperature; Choice Behavior; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Dronabinol; Drug Users; Female; GABA Modulators; Heart Rate; Humans; Hydromorphone; Male; Marijuana Smoking; Methylphenidate; Psychomotor Performance; Reinforcement, Psychology; Respiration; Skin Temperature; Triazolam | 2010 |
Within-subject, double-blinded, randomized, and placebo-controlled evaluation of the combined effects of the cannabinoid dronabinol and the opioid hydromorphone in a human laboratory pain model.
Topics: Adult; Analgesics, Opioid; Cannabinoids; Double-Blind Method; Dronabinol; Humans; Hydromorphone; Laboratories; Pain | 2021 |
Within-subject, double-blind, randomized, placebo-controlled evaluation of combining the cannabinoid dronabinol and the opioid hydromorphone in adults with chronic pain.
Topics: Adult; Analgesics; Analgesics, Opioid; Cannabinoids; Chronic Pain; Double-Blind Method; Dronabinol; Female; Humans; Hydromorphone; Male; Middle Aged; Osteoarthritis, Knee | 2023 |
7 other study(ies) available for dronabinol and hydromorphone
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
An estimate of the proportion of drug-facilitation of sexual assault in four U.S. localities.
Topics: Adolescent; Adult; Ambulatory Care Facilities; Amitriptyline; Central Nervous System Depressants; Cocaine; Dopamine Uptake Inhibitors; Doxylamine; Dronabinol; Ethanol; Female; Flunitrazepam; Forensic Toxicology; Hair; Histamine H1 Antagonists; Humans; Hydromorphone; Male; Narcotics; Nortriptyline; Oxazepam; Oxycodone; Psychotropic Drugs; Sex Offenses; Substance Abuse Detection; United States | 2007 |
Substitution profile of Delta9-tetrahydrocannabinol, triazolam, hydromorphone, and methylphenidate in humans discriminating Delta9-tetrahydrocannabinol.
Topics: Administration, Oral; Adult; Case-Control Studies; Discrimination, Psychological; Double-Blind Method; Dronabinol; Female; Humans; Hydromorphone; Male; Marijuana Abuse; Methylphenidate; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Surveys and Questionnaires; Triazolam; Young Adult | 2009 |
Rapid Extraction and Qualitative Screening of 30 Drugs in Oral Fluid at Concentrations Recommended for the Investigation of DUID Cases.
Topics: 2-Propanol; 3,4-Methylenedioxyamphetamine; Alprazolam; Amphetamines; Buprenorphine; Carisoprodol; Clonazepam; Cocaine; Codeine; Dronabinol; Fentanyl; Hexanes; Hydrocodone; Hydromorphone; Lorazepam; Meprobamate; Methadone; Methamphetamine; Morphine Derivatives; N-Methyl-3,4-methylenedioxyamphetamine; Nordazepam; Oxazepam; Oxycodone; Oxymorphone; Pharmaceutical Preparations; Phencyclidine; Tandem Mass Spectrometry; Temazepam; Tramadol; Zolpidem | 2022 |